Pilavapadin
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Pilavapadin
- Molecular weight
- 385.41
- Structure (SMILES)
- CC(C)C[C@](C)(N)COc1ccc(-c2ccnc(C(F)F)c2)nc1C(F)F
- aak1 in 1
- AAK1-IN-1
- bms 986176
- BMS-986176
- lx 9211
- LX-9211
- lx9211
- Lx9211
- LX9211
- LX9211 (blinded)
- pilavapadin
- Pilavapadin
- pilavapadin [INN]
- PILAVAPADIN [USAN]
- pilavapadin inn
- pilavapadin usan
- pilavapadina
- Pilavapadina
- pilavapadine
- Pilavapadine
- CAS registry numbers
- 1815613-42-3
- ChEMBL ID
- CHEMBL5089410
- InChIKey
- RKAHOQATMSONTM-IBGZPJMESA-N
- PubChem compound IDs
- 118419773
- FDA ingredient codes (UNII)
- 9G4RLM5X6Z
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- pilavapadin
- Type
- Synthetic organic
- Drug name stem
- -padin
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- AP2 associated kinase 1
- Gene symbol
- AAK1
- Protein identifier
- Q2M2I8
- Median affinity
- 8.7
- Affinity units
- pIC50
Investigated indications
- Condition
- Neuralgia, Postherpetic
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0041052
- Subject identifier
- D051474
- Condition identifier
- EFO_0005762
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0041052
- Highest recorded phase
- 2
Trial references
- NCT04662281
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 61.03
- Calculated partition coefficient (ALogP)
- 5.16
- Calculated partition coefficient (XLogP)
- 3.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 8
- Heavy atoms
- 27
- Molecular formula
- C19H23F4N3O
- Monoisotopic mass
- 385.17772501
- Natural product
- No
- Recorded assays
- 237
- Active assays
- 43
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (3)
- A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
- Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia
- Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
In development for (1)
- Postherpetic neuralgia Phase 2